Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
AiLAB SWISS is a Swiss pharmaceutical company and analytical laboratory specializing in the production and analysis of cannabis-derived compounds. Operating as a division of Ai Fame GmbH, the company provides integrated manufacturing services for pharmaceutical-grade cannabinoids and active pharmaceutical ingredients (APIs). Its state-of-the-art facility in Wald-Schönengrund focuses on high-precision plant analysis and quality control to ensure compliance with medical standards. AiLAB SWISS serves the healthcare and life sciences sectors by delivering standardized cannabinoid products for therapeutic use in areas such as pain management and neurology. The company's expertise in extraction and analytical chemistry supports the development of high-quality medical cannabis products for the European market.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on AiLAB SWISS.